BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 181.97 |
| Open | 179.62 |
| Bid | 179.17 x 800 |
| Ask | 179.43 x 800 |
| Day's Range | 178.04 - 183.10 |
| 52 Week Range | 156.56 - 280.62 |
| Volume | |
| Avg. Volume | 212,280 |
| Market Cap | 19.85B |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 29, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad hematology portfolio, with invited speakers presenting key data from the ASH 2023.
- Business Wire
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 28, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 9-12 in San Diego, California. BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.
- Business Wire
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & WALTHAM, Mass., November 21, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
